AMAL Therapeutics finalises €29 million (CHF 33.2 million) Series B round

Geneva, Switzerland – 12 September 2018 – AMAL Therapeutics (AMAL), the Swiss biotech developing novel, peptide-based therapeutic cancer vaccines, today announces that it has completed the second closing of its Series B financing round. The second and final tranche of €21.2 million (CHF 24.2 million) brings the total round to just over €29 million (CHF 33.2 million).

View PDF